QLT announces positive findings from Phase IV G6PD deficiency study for Aczone(TM) in acne.
Company to Pursue Discussions with FDA on Labeling VANCOUVER, Nov. 7 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) today announced positive results of a Phase IV clinical trial of Aczone(TM) in more than 50 patients with G6PD deficiency that was performed to meet a post-approval commitment...

Curing Kids' Cancer Announces 2006 Pediatric Cancer Research Grants.
Johns Hopkins research into childhood leukemia awarded primary grant ATLANTA, Jan. 8 /PRNewswire-USNewswire/ -- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins has been named the primary recipient of the 2006 grants from Curing Kids' Cancer, the charity that raises money for leading edge pediatric cancer...

Keeping Cancer At Bay: Long-Term Therapy In the Fight Against Multiple Myeloma.
WASHINGTON, Nov. 3 /PRNewswire/ -- There is no known cure for multiple myeloma, so its diagnosis means high-dose chemotherapy followed by repeated treatments with each relapse of the cancer -- a watch and wait approach. A new approach of providing patients with continuous therapy to keep the cancer at...

Cingular Wireless Joins PADRES to Fight Childhood Cancer.
Promotion Expected To Raise Critical Funds & Increase Bone Marrow Donations LOS ANGELES, Nov. 7 /PRNewswire/ -- PADRES Contra El Cancer (PADRES) joins forces with Cingular Wireless to launch an extraordinary promotion to benefit children and families fighting childhood cancer. The campaign is a partnership...

Blood and Circulatory Disorders Sourcebook.
Edited by Shin, Linda M. and Bellenir, Karen. 575 pp. Illustrated. Indexed. Detroit, MI (Omni Graphics, Inc.), 1998. $78.00 ISBN # 0780802039 Blood and Circulatory Disorders Sourcebook is part of a series of resource books on topics of medical concern. This text provides a concise overview of...

Lipoxen Announces $75M Agreement With Baxter to Develop New Blood Clotting Factors.
LONDON, December 15 /PRNewswire-FirstCall/ -- Lipoxen PLC today announced that the company has entered into an exclusive worldwide development and licence agreement with a subsidiary of Baxter International Inc. to develop improved, longer-acting forms of blood-clotting factors. The signing of this agreement by Baxter triggers a $1...

Baxter Announces Therapeutic Development Program for First Blood-Free Recombinant von Willebrand Factor.
Initial Results of Biochemical and Preclinical Characterization of Therapeutic Candidate Presented at ASH ORLANDO, Fla., Dec. 11 /PRNewswire-FirstCall/ -- Baxter Healthcare Corporation today announced that the company has initiated a therapeutic program for the development of a recombinant form of von Willebrand factor (VWF), a protein critical...

EPA and DOJ Reach Agreement With Von Roll on Clean-Air and Hazardous-Waste Violations.
CHICAGO, Dec. 1 /PRNewswire/ -- U.S. Environmental Protection Agency and U.S. Department of Justice have reached an agreement with Von Roll America Inc. on alleged clean-air and hazardous-waste violations at the company's commercial hazardous waste incinerator at 1250 St. George St., East Liverpool, Ohio. The consent decree...

Baxter Presents Preclinical Studies of Experimental Longer-Acting Hemophilia A Therapy.
Preclinical Evidence Suggests Modified von Willebrand Factor Extends Factor VIII Half-Life in a Mouse Model of Hemophilia A ORLANDO, Fla., Dec. 11 /PRNewswire-FirstCall/ -- Baxter Healthcare Corporation today announced the presentation of preclinical data from ongoing research studies aimed at developing a novel, longer-acting form of factor...

Straight Answers.
Byline: GAURAV THAKUR DR SHASHIKANT APTE, Head, (Haematology), Sahyadri Laboratory and Haematology Center, On haematology cases in Pune. Has there been a rise in haematology related cases in Pune? Yes, there has been a substantial rise in such cases with respect to Pune....